Gan & Lee Pharmaceuticals announced the appointment of Dr. Ting JIA as Chief Medical Officer (CMO). In this role, Dr. Jia will oversee clinical development, registration strategy, and cross-functional coordination for the company?s pipeline products in Europe and the United States. Her leadership will accelerate the global commercialization of Gan & Lee?s innovative drugs and advance the company?s mission to deliver breakthrough therapies to patients worldwide.
Dr. Jia earned her Doctor of Medicine degree and completed her postdoctoral research at Karolinska Institute in Sweden. With over 15 years of experience in metabolic diseases, she has led research and global clinical development in diabetes, obesity, kidney disorders, and other chronic metabolic conditions. Dr. Jia combines a solid academic foundation with extensive multinational project management experience.
Before joining Gan & Lee, Dr. Jia held key leadership positions at Novo Nordisk, where she managed the full lifecycle of multiple innovative drugs. She was responsible for developing clinical strategies, designing and executing study protocols, and successfully advancing several products through approvals and indication expansions in the U.S., Europe, China, and other major markets. This appointment marks a significant step in Gan & Lee?s global R&D expansion and internationalization strategy, further strengthening the company?s global competitiveness in the field of endocrine and metabolic disease treatment.
